1.Development of an animal model of blood stasis syndrome and thrombosis.
Ai-hua LIANG ; Xiao-shuang DING ; Wen LI ; Bao-yun XUE ; Jin-hua WANG ; Hong-jun YANG
China Journal of Chinese Materia Medica 2005;30(20):1613-1616
OBJECTIVETo develop an animal model of thrombosis and blood stasis syndrome in rats by using lipopolysaccharide (LPS) in combination with carrageenan (Ca).
METHODSD rats in control group were randomly divided into control group and model group (LPS/Ca treatment). The rats in model group were firstly treated with Ca ip, and followed by LPS iv sixteen hours later. The rats in control group were given normal saline (NS). The moment of LPS iv was served as 0 h for the observation. The ear microcirculation, blood rheology parameters (whole blood viscosity etab, plasma viscosity etap and platelet aggregation PA), cruor parameters (thrombin time TT, prothrombin time PT, and partial thromboplastin time APIT) and inflammation factors (TNFalpha, IL-6) were observed at different time after treatment.
RESULTLPS/Ca combinatory treatment can induce a stable and repeatable thrombosis animal model. The thrombus can be observed on the tails of rats by naked eyes, and can be quantitatively measured without necessary of autopsy. Obstacle in microcirculation, increase in whole blood viscosity (etab) and a change of platelets aggregation (PA) rate were observed after LPS/Ca treatment. Cruor parameters were significantly prolonged due to large consumption of cruor factors and platelets. The concentration of inflammation factors TNFalpha and IL-6 in blood was obviously increased at the early stage of the model. The results indicate that this animal model has the characteristics of blood stasis syndrome caused by pyrogen and toxin accompanied by thrombosis.
CONCLUSIONLPS/Ca combinatory treatment can induce a easily practicable and repeatable animal model characterized as thrombosis and blood stasis syndrome
Animals ; Blood Coagulation Disorders ; blood ; chemically induced ; Blood Viscosity ; Carrageenan ; Disease Models, Animal ; Interleukin-6 ; blood ; Lipopolysaccharides ; Male ; Microcirculation ; Platelet Aggregation ; Prothrombin Time ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; Thrombin Time ; Thrombosis ; blood ; chemically induced ; Tumor Necrosis Factor-alpha ; metabolism
2.Ellagic acid-induced hypercoagulable state in animals: a potentially useful animal hypercoagulable model for evaluation of anticoagulants.
Liu NA ; Liu JUN-TIAN ; Zhang QIANG-ZONG
Chinese Medical Sciences Journal 2010;25(4):237-242
OBJECTIVETo establish and evaluate a hypercoagulable animal model for the assessment of anticoagulants.
METHODSForty mice, thirty-two rats, and twenty-four rabbits were randomly and equally divided into control group (saline) and three ellagic acid (EA)-treated groups (low, middle, and high doses). In the mice, bleeding time (BT) was estimated with tail transaction, and clotting time (CT) with template method. Prothrombin time (PT) and the activated partial thromboplastin time (APTT) in rats and rabbits were measured by means of Quick's one-stage assay and modified APTT assay respectively. In addition, thrombin activity was estimated in rats with PT assay using a hemagglutination analyzer. The circulating platelet aggregates were detected in rabbits through platelet counting and presented as the circulating platelet aggregate ratio (CPAR).
RESULTSEA shortened BT and CT in mice, PT and APTT in rats, and increased thrombin activity and CPAR, all in a dose-dependent manner. EA also brought reduction of PT and APTT in rabbits in dose- and time-dependent manners.
CONCLUSIONEA could induce hypercoagulable state through activating coagulation system and platelets in mice, rats, and rabbits.
Animals ; Anticoagulants ; therapeutic use ; Blood Coagulation Disorders ; chemically induced ; drug therapy ; Drug Evaluation, Preclinical ; Ellagic Acid ; adverse effects ; Female ; Male ; Mice ; Mice, Inbred ICR ; Models, Animal ; Platelet Aggregation ; drug effects ; Prothrombin Time ; Rabbits ; Rats ; Rats, Sprague-Dawley
3.Comparison of the Safety of Seven Iodinated Contrast Media.
Jong Mi SEONG ; Nam Kyong CHOI ; Joongyub LEE ; Yoosoo CHANG ; Ye Jee KIM ; Bo Ram YANG ; Xue Mei JIN ; Ju Young KIM ; Byung Joo PARK
Journal of Korean Medical Science 2013;28(12):1703-1710
We aimed to determine the characteristic adverse events (AEs) of iodinated contrast media (IOCM) and to compare the safety profiles of different IOCM. This study used the database of AEs reports submitted by healthcare professionals from 15 Regional Pharmacovigilance Centers between June 24, 2009 and December 31, 2010 in Korea. All reports of IOCM, including iopromide, iohexol, iopamidol, iomeprol, ioversol, iobitridol and iodixanol, were analyzed. Safety profiles were compared between different IOCM at the system organ level using the proportional reporting ratio (PRR) and 95% confidence interval (95% CI). Among a total of 48,261 reports, 6,524 (13.5%) reports were related to the use of IOCM. Iopromide (45.5%), iohexol (16.9%), iopamidol (14.3%) and iomeprol (10.3%) were identified as frequently reported media. 'Platelet, bleeding & clotting disorders' (PRR, 29.6; 95%CI, 1.9-472.6) and 'urinary system disorders' (PRR, 22.3; 95% CI, 17.1-29.1) were more frequently reported for iodixanol than the other IOCM. In conclusion, the frequency of AEs by organ class was significantly different between individual media. These differences among different IOCM should be considered when selecting a medium among various IOCM and when monitoring patients during and after its use to ensure optimum usage and patient safety.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Blood Platelet Disorders/chemically induced
;
Child
;
Child, Preschool
;
Contrast Media/*adverse effects/diagnostic use
;
Databases, Factual
;
Female
;
Humans
;
Infant
;
Infant, Newborn
;
Iodine Radioisotopes/chemistry
;
Male
;
Middle Aged
;
Neoplasms/radionuclide imaging
;
Radiopharmaceuticals/*adverse effects/diagnostic use
;
Urologic Diseases/chemically induced
;
Young Adult